S&P 500 7,470.86 â–ŧ 29.72 (-0.40%) DOW 51,702.74 ▲ 138.04 (+0.27%) NASDAQ 26,156.81 â–ŧ 361.12 (-1.36%) US Markets Closed â€ĸ 05:39 PM ET

PEPG

PepGen Inc.

Price Chart
Latest Quote

$1.79

+0.09 (+5.29%)
Current Price
Previous Close $1.70
Open $1.72
Day High $1.81
Day Low $1.72
Volume 692,233
Fetched: 2026-06-22T11:58:02
Stock Information
Shares Outstanding 69.17M
Total Debt $16.56M
Cash Equivalents $132.30M
Net Income $-77.22M
Sector Healthcare
Industry Biotechnology
Market Cap $126.58M
EPS (TTM) $-1.45
Exchange NMS
🌐 Visit Website
📊 Comprehensive Analysis
Company Data
Enterprise Value$8.07M
Income$-77.22M
Book/sh$1.94
Cash/sh$1.91
Employees59
Financial Ratios
Quick Ratio14.76
Current Ratio14.98
Debt/Eq12.36
Returns & Margins
ROA-35.79%
ROE-68.40%
Ownership
Insider Ownership0.23%
Institutional Ownership90.16%
Insider & Institutional transactions data not available
Valuation Ratios
Forward P/E-1.49
P/B0.94
Analyst Data
Recommendationstrong_buy
Target Price$10.25
Technical Indicators
SMA20$1.52
SMA50$1.60
SMA200$4.06
RSI72.50
ATR0.1048
Shares Float36.05M
Short Float7.65%
Short Ratio4.38
Volatility1.93
Rel Volume1.99
Performance History
Week+24.49%
Month+27.08%
Quarter-61.06%
6 Months-65.28%
YTD-74.48%
Year+24.49%
3 Years-85.00%
10 Years-85.80%
Stock Score: ⭐ Premium
Based on debt, profitability, growth, and cash flow metrics
⭐ Premium Feature

Sign up for free to view detailed scoring breakdown — premium is free during our trial period!

Recent Price History
Date Close Volume
2026-06-22 $1.83 1,350,074
2026-06-18 $1.79 692,200
2026-06-17 $1.70 1,256,300
2026-06-16 $1.59 1,171,800
2026-06-15 $1.53 454,100
2026-06-12 $1.47 221,200
2026-06-11 $1.51 631,300
2026-06-10 $1.38 478,000
2026-06-09 $1.38 1,051,800
2026-06-08 $1.35 474,500
2026-06-05 $1.41 604,100
2026-06-04 $1.48 481,400
2026-06-03 $1.42 463,300
2026-06-02 $1.45 666,400
2026-06-01 $1.47 519,000
2026-05-29 $1.50 596,100
2026-05-28 $1.50 707,200
2026-05-27 $1.52 669,000
2026-05-26 $1.53 501,600
About PepGen Inc.

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.

Period:
Loading...
Income Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Revenue
Total Revenue $0 $0 $0 $0
Operating Revenue $0 $0 $0 $0
Expenses
Total Expenses $93,612,000 $97,739,000 $84,766,000 $68,301,000
Other Income Expense $-11,000 $-1,000 $-187,000 $110,000
Other Non Operating Income Expenses $-11,000 $-1,000 $-187,000 $110,000
Net Non Operating Interest Income Expense $4,017,000 $7,142,000 $6,400,000 $2,793,000
Operating Expense $93,612,000 $97,739,000 $84,766,000 $68,301,000
General And Administrative Expense $22,569,000 $21,261,000 $16,640,000 $14,224,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest $-89,655,000 $-89,981,000 $-78,626,000 $-69,104,000
Net Interest Income $4,017,000 $7,142,000 $6,400,000 $2,793,000
Interest Income $4,017,000 $7,142,000 $6,400,000 $2,793,000
Normalized Income $-89,655,000 $-89,981,000 $-78,626,000 $-69,104,000
Net Income From Continuing And Discontinued Operation $-89,655,000 $-89,981,000 $-78,626,000 $-69,104,000
Total Operating Income As Reported $-93,612,000 $-97,739,000 $-84,766,000 $-68,301,000
Net Income Common Stockholders $-89,655,000 $-89,981,000 $-78,626,000 $-69,104,000
Net Income $-89,655,000 $-89,981,000 $-78,626,000 $-69,104,000
Net Income Including Noncontrolling Interests $-89,655,000 $-89,981,000 $-78,626,000 $-69,104,000
Net Income Continuous Operations $-89,655,000 $-89,981,000 $-78,626,000 $-69,104,000
Pretax Income $-89,606,000 $-90,598,000 $-78,553,000 $-65,398,000
Interest Income Non Operating $4,017,000 $7,142,000 $6,400,000 $2,793,000
Operating Income $-93,612,000 $-97,739,000 $-84,766,000 $-68,301,000
Per Share
Diluted EPS $-2.12 $-2.85 $-3.30 $-2.91
Basic EPS $-2.12 $-2.85 $-3.30 $-2.91
Other
Tax Effect Of Unusual Items $0 $0 $0 $0
Tax Rate For Calcs $0 $0 $0 $0
Normalized EBITDA (Bullshit earnings) $-88,467,000 $-92,486,000 $-83,916,000 $-67,808,000
Reconciled Depreciation $5,145,000 $5,253,000 $850,000 $493,000
EBITDA (Bullshit earnings) $-88,467,000 $-92,486,000 $-83,916,000 $-67,808,000
EBIT $-93,612,000 $-97,739,000 $-84,766,000 $-68,301,000
Diluted Average Shares $42,221,808 $31,583,073 $23,796,000 $23,713,196
Basic Average Shares $42,221,808 $31,583,073 $23,796,000 $23,713,196
Diluted NI Availto Com Stockholders $-89,655,000 $-89,981,000 $-78,626,000 $-69,104,000
Tax Provision $49,000 $-617,000 $73,000 $3,706,000
Research And Development $71,043,000 $76,478,000 $68,126,000 $54,077,000
Selling General And Administration $22,569,000 $21,261,000 $16,640,000 $14,224,000
Other Gand A $22,569,000 $21,261,000 $16,640,000 $14,224,000
Otherunder Preferred Stock Dividend - - - -
Fetched: 2026-06-19
Balance Sheet (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Assets
Net Tangible Assets $147,444,000 $118,620,000 $108,421,000 $179,631,000
Total Assets $173,907,000 $150,883,000 $143,052,000 $217,440,000
Total Non Current Assets $22,944,000 $27,122,000 $30,374,000 $31,357,000
Other Non Current Assets $1,920,000 $1,974,000 $1,990,000 $1,473,000
Current Assets $150,963,000 $123,761,000 $112,678,000 $186,083,000
Other Current Assets $2,507,000 $3,570,000 $2,271,000 $4,331,000
Cash Cash Equivalents And Short Term Investments $148,456,000 $120,191,000 $110,407,000 $181,752,000
Cash And Cash Equivalents $60,514,000 $49,421,000 $80,774,000 $181,752,000
Receivables - - - $58,000
Other Receivables - - - $58,000
Prepaid Assets - - - -
Debt
Total Debt $17,004,000 $18,661,000 $20,104,000 $24,534,000
Long Term Debt And Capital Lease Obligation $13,817,000 $15,567,000 $17,100,000 $18,981,000
Current Debt And Capital Lease Obligation $3,187,000 $3,094,000 $3,004,000 $5,553,000
Liabilities
Total Liabilities Net Minority Interest $26,463,000 $32,263,000 $34,631,000 $37,809,000
Total Non Current Liabilities Net Minority Interest $13,817,000 $15,567,000 $17,100,000 $18,981,000
Current Liabilities $12,646,000 $16,696,000 $17,531,000 $18,828,000
Payables And Accrued Expenses $4,796,000 $9,985,000 $12,159,000 $10,835,000
Payables $822,000 $1,752,000 $1,005,000 $3,936,000
Accounts Payable $822,000 $1,752,000 $1,005,000 $1,362,000
Total Tax Payable - - $0 $2,574,000
Derivative Product Liabilities - - - $0
Equity
Common Stock Equity $147,444,000 $118,620,000 $108,421,000 $179,631,000
Total Equity Gross Minority Interest $147,444,000 $118,620,000 $108,421,000 $179,631,000
Stockholders Equity $147,444,000 $118,620,000 $108,421,000 $179,631,000
Gains Losses Not Affecting Retained Earnings $11,000 $23,000 $34,000 $-81,000
Other Equity Adjustments $11,000 $23,000 $34,000 $-81,000
Retained Earnings $-361,118,000 $-271,463,000 $-181,482,000 $-102,856,000
Preferred Stock Equity - - - -
Other
Ordinary Shares Number $68,874,944 $32,619,663 $23,823,241 $23,713,196
Share Issued $68,874,944 $32,619,663 $23,823,241 $23,713,196
Tangible Book Value $147,444,000 $118,620,000 $108,421,000 $179,631,000
Invested Capital $147,444,000 $118,620,000 $108,421,000 $179,631,000
Working Capital $138,317,000 $107,065,000 $95,147,000 $167,255,000
Capital Lease Obligations $17,004,000 $18,661,000 $20,104,000 $24,534,000
Total Capitalization $147,444,000 $118,620,000 $108,421,000 $179,631,000
Additional Paid In Capital $508,544,000 $390,057,000 $289,867,000 $282,566,000
Capital Stock $7,000 $3,000 $2,000 $2,000
Common Stock $7,000 $3,000 $2,000 $2,000
Preferred Stock $0 $0 $0 $0
Long Term Capital Lease Obligation $13,817,000 $15,567,000 $17,100,000 $18,981,000
Current Capital Lease Obligation $3,187,000 $3,094,000 $3,004,000 $5,553,000
Pensionand Other Post Retirement Benefit Plans Current $4,663,000 $3,617,000 $2,368,000 $2,440,000
Current Accrued Expenses $3,974,000 $8,233,000 $11,154,000 $6,899,000
Net PPE $21,024,000 $25,148,000 $28,384,000 $29,884,000
Accumulated Depreciation $-3,911,000 $-3,046,000 $-1,572,000 $-389,000
Gross PPE $24,935,000 $28,194,000 $29,956,000 $30,273,000
Construction In Progress $20,000 $96,000 $69,000 $1,129,000
Other Properties $23,156,000 $26,542,000 $28,441,000 $2,424,000
Machinery Furniture Equipment $1,759,000 $1,556,000 $1,446,000 $171,000
Other Short Term Investments $87,942,000 $70,770,000 $29,633,000 $0
Treasury Shares Number - - $0 -
Leases - - $23,620,000 $26,549,000
Properties - - $0 $0
Fetched: 2026-06-19
Cash Flow Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Free Cash Flow
Free Cash Flow $-81,899,000 $-82,869,000 $-71,596,000 $-63,020,000
Operating Activities
Operating Cash Flow $-81,635,000 $-82,372,000 $-68,997,000 $-59,265,000
Cash Flow From Continuing Operating Activities $-81,635,000 $-82,372,000 $-68,997,000 $-59,265,000
Operating Gains Losses - - - $76,000
Investing Activities
Capital Expenditure $-264,000 $-497,000 $-2,599,000 $-3,755,000
Investing Cash Flow $-15,235,000 $-37,668,000 $-32,003,000 $-3,755,000
Cash Flow From Continuing Investing Activities $-15,235,000 $-37,668,000 $-32,003,000 $-3,755,000
Financing Activities
Issuance Of Capital Stock $108,100,000 $86,778,000 $0 $114,267,000
Financing Cash Flow $107,979,000 $88,749,000 $-189,000 $112,193,000
Cash Flow From Continuing Financing Activities $107,979,000 $88,749,000 $-189,000 $112,193,000
Net Other Financing Charges $-413,000 $-511,000 $-442,000 $-2,697,000
Net Common Stock Issuance $108,100,000 $86,778,000 $0 $114,267,000
Common Stock Issuance $108,100,000 $86,778,000 $0 $114,267,000
Net Preferred Stock Issuance - - - $0
Preferred Stock Issuance - - - $0
Other
Income Tax Paid Supplemental Data $82,000 $71,000 $2,702,000 $0
End Cash Position $62,062,000 $50,969,000 $82,322,000 $183,225,000
Beginning Cash Position $50,969,000 $82,322,000 $183,225,000 $134,368,000
Effect Of Exchange Rate Changes $-16,000 $-62,000 $286,000 $-316,000
Changes In Cash $11,109,000 $-31,291,000 $-101,189,000 $49,173,000
Proceeds From Stock Option Exercised $292,000 $2,482,000 $253,000 $623,000
Net Investment Purchase And Sale $-14,971,000 $-37,171,000 $-29,404,000 $0
Sale Of Investment $79,000,000 $108,000,000 $0 -
Purchase Of Investment $-93,971,000 $-145,171,000 $-29,404,000 $0
Net PPE Purchase And Sale $-264,000 $-497,000 $-2,599,000 $-3,755,000
Purchase Of PPE $-264,000 $-497,000 $-2,599,000 $-3,755,000
Change In Working Capital $-6,223,000 $-5,246,000 $1,951,000 $4,507,000
Change In Other Current Liabilities $-3,094,000 $-3,004,000 $-1,166,000 $-2,016,000
Change In Payables And Accrued Expense $-4,203,000 $-941,000 $1,053,000 $4,124,000
Change In Accrued Expense $-3,268,000 $-1,663,000 $1,422,000 $5,531,000
Change In Payable $-935,000 $722,000 $-369,000 $-1,407,000
Change In Account Payable $-935,000 $722,000 $-369,000 $-1,407,000
Change In Prepaid Assets $1,074,000 $-1,301,000 $2,064,000 $-1,784,000
Stock Based Compensation $10,609,000 $11,457,000 $7,048,000 $4,763,000
Asset Impairment Charge $701,000 $0 - -
Amortization Of Securities $-2,212,000 $-3,925,000 $-220,000 $0
Depreciation Amortization Depletion $5,145,000 $5,253,000 $850,000 $493,000
Depreciation And Amortization $5,145,000 $5,253,000 $850,000 $493,000
Amortization Cash Flow $3,748,000 $3,748,000 $-334,000 $0
Amortization Of Intangibles $3,748,000 $3,748,000 $-334,000 $0
Depreciation $1,397,000 $1,505,000 $1,184,000 $493,000
Net Income From Continuing Operations $-89,655,000 $-89,981,000 $-78,626,000 $-69,104,000
Other Non Cash Items - $70,000 - $134,000
Change In Receivables - - $26,000 $4,183,000
Gain Loss On Sale Of PPE - - $0 $134,000
Change In Other Current Assets - - - $0
Gain Loss On Investment Securities - - - $-58,000
Fetched: 2026-06-19